

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
IDEC Pharmaceuticals Corporation	08/03/2004
SEIKAGAKU Corporation	07/12/2004
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BIOGEN IDEC MA Inc.
<b>Street Address:</b>	14 Cambridge Center
<b>City:</b>	Cambridge
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02142
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	10951140
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)371-2540
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Phone:</b>	202-371-2700
<b>Email:</b>	ckim@skgf.com
<b>Correspondent Name:</b>	Sterne, Kessler, Goldstein & Fox, PLLc
<b>Address Line 1:</b>	1100 New York Avenue, NW
<b>Address Line 4:</b>	Washington, DISTRICT OF COLUMBIA 20005
<b>ATTORNEY DOCKET NUMBER:</b>	2159.2350005/EJH/C-K
<b>NAME OF SUBMITTER:</b>	/s/Ji Eun Kim L0403/
<b>Total Attachments: 3</b> source=21592350005Assignment#page1.tif source=21592350005Assignment#page2.tif source=21592350005Assignment#page3.tif	

OP \$40.00 10951140

## ASSIGNMENT

THIS ASSIGNMENT, by IDEC Pharmaceuticals Corporation, a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 3030 Callan Road, San Diego, California 92121 and by SEIKAGAKU CORPORATION, a corporation duly organized under and pursuant to the laws of Japan, and having its principal place of business at 2-1-5, Nihonbashi-Honcho, Chuo-Ku, Tokyo Yakugyo Bldg., Tokyo 103, Japan (hereinafter referred to as "the Assignors"), witnesseth:

WHEREAS, the Assignors presently own certain new and useful improvements in GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS, which are set forth in each of the national applications identified in Appendix A (attached hereto); and

WHEREAS, Biogen Idec MA Inc., a corporation duly organized under and pursuant to the laws of Massachusetts, and having its principal place of business at 14 Cambridge Center, Cambridge, MA 02142 (hereinafter referred to as "the Assignee"), is desirous of acquiring the entire right, title, and interest in and to all patents and applications identified in Appendix A, and any applications, claiming priority to said application, including provisional applications for Letters Patent of the United States and applications for patent in other countries, and any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon.

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignors have sold, assigned, transferred, and set over, and by these presents do sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to the inventions for new and useful improvements in GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS, which are set forth in each of the national applications identified in Appendix A (attached hereto), the right to file applications on said inventions and the entire right, title, and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said applications, and any and all Letters Patent of the United States of America and all foreign countries that may be granted therefor and thereon, and in and to any and all applications claiming priority to said applications, divisions, continuations, and continuations-in-part of said applications, and reissues and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignors had this sale and assignment not been made;

AND for the same consideration, the Assignors hereby covenant and agree to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, the Assignors are the sole and lawful owners of the entire right, title, and interest in and to the inventions set forth in said applications and said applications, including provisional applications, above-mentioned, and that the same are unencumbered, and that the Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth;

AND for the same consideration, the Assignors hereby covenant and agree to and with the Assignee, its successors, legal representatives, and assigns that the Assignors will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said inventions or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said inventions in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said application, division, continuation, or continuation-in-part of any applications for Letters Patent or Patents, or any reissue or extension of any Letters Patent or Patents to be obtained


thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement, and defense of all Letters Patent or Patents for said inventions, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignors hereby request the Commissioner of Patents of the United States Patent and Trademark Office to issue any and all said Letters Patent of the United States to the Assignee as the Assignee of said inventions, the Letters Patent to be issued for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date 8-3-04

Signature of Assignor   
IDEC PHARMACEUTICALS  
CORPORATION


Date 8-3-04

Signature of Witness 

Date July 12, 2004

Signature of Assignor   
SEIKAGAKU CORPORATION

Date Aug. 5, 2004

Signature of Witness 

Date Aug. 3, 2004

Signature of Assignor   
BIOGEN IDEC MA INC.

Date 8/3/04

Signature of Witness 

**APPENDIX A**

<b><u>Country</u></b>	<b><u>Application/Patent No.</u></b>	<b><u>Filing/Issue Date</u></b>
Australia	725482; 61469/98	2/17/98*; 1/25/01
Austria	98906171.8	2/17/98*
Belgium	98906171.8	2/17/98*
Brazil	PI9807437-7	2/17/98*
Canada	2281893	2/17/98*
China	98804345.9	2/17/98*
Denmark	98906171.8	2/17/98*
Europe	98906171.8	2/17/98*
Finland	98906171.8	2/17/98*
France	98906171.8	2/17/98*
Germany	98906171.8	2/17/98*
Great Britain	98906171.8	2/17/98*
Greece	98906171.8	2/17/98*
Hong Kong	00105303.1	8/23/00
Hungary	P0001318	2/17/98*
India	427/DEL/1998	2/19/98
India	484/DEL/2002	4/22/02
Indonesia	W-991061	2/17/98*
Ireland	98906171.8	2/17/98*
Israel	131448	2/17/98*
Israel	159642	12/29/03
Italy	98906171.8	2/17/98*
Japan	10-536675	2/17/98*
Korea (South)	1999-7007604	2/17/98*
Luxembourg	98906171.8	2/17/98*
Malaysia	PI9800732	2/20/98
Mexico	997688	2/17/98*
Monaco	98906171.8	2/17/98*
Netherlands	98906171.8	2/17/98*
New Zealand	337601; 337601	2/17/98*; 9/7/00
Norway	19994006	2/17/98*
Pakistan	136812; 341/99	2/19/98; 4/30/99
Portugal	98906171.8	2/17/98*
PCT	PCT/US98/02253	2/17/98
Philippines	01-1998-00383	2/20/98
Russia	2206614; 99120076	2/17/98*; 6/20/03
Singapore	9903998-4	2/17/98*
South Africa	98/1434; 98/1434	2/20/98*; 10/28/98
Spain	98906171.8	2/17/98*
Sweden	98906171.8	2/17/98*
Switzerland	98906171.8	2/17/98*
Taiwan	87102442	2/20/98
Thailand	042357	2/19/98
United States	08/803,085; 6,011,138	2/20/97; 1/4/00
United States	09/292,053	4/14/99
United States	09/019,441	2/5/98
United States	10/103,686	3/25/02

\*International filing date of PCT/US98/02253